21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer
BySara A. Hurvitz, MD,Michal Jarzab,Montserrat Munoz Mateu,Erin Cobain,Jin Zhang,Arielle Medford,Alistair Ring,Priyanka Sharma, MD,Christian Schem, MD,Ionut Temciuc,Zheng Li,Juan Pablo Zarate,Denise A. Yardley, MD
Published: | Updated:
